false 0001616543 0001616543 2023-11-09 2023-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549








Date of Report (Date of earliest event reported): November 9, 2023


(Exact Name of Registrant as Specified in its Charter)


Delaware   001-37717   47-1210911
(State or Other
Jurisdiction of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)


20451 Seneca Meadows Parkway
Germantown, MD 20876-7005
(Address of Principal Executive Office) (Zip Code)


Registrant's telephone number, including area code: (301) 515-7260


Not Applicable

Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock SENS NYSE American


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 2.02. Results of Operations and Financial Condition.


On November 9, 2023, Senseonics Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights and outlook. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by this reference.


The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.


Item 9.01. Financial Statements and Exhibits.




Number   Description
99.1   Press Release of Senseonics Holdings, Inc. dated November 9, 2023.
104   Cover Page Interactive Data (embedded within the Inline XBRL document).






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 9, 2023 SENSEONICS HOLDINGS, INC.
  By: /s/ Rick Sullivan
  Name: Rick Sullivan
  Title: Chief Financial Officer




Exhibit 99.1





GERMANTOWN, MD, November 9, 2023 —Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2023.


Recent Highlights & Accomplishments:


·Generated revenue of $6.1 million in the third quarter of 2023


·Announced the last patient completion of the 365-day ENHANCE Pivotal Clinical Study adult cohort


·Launched with our global commercial partner Ascensia Diabetes Care, a new direct to consumer U.S. advertising campaign, ‘The CGM for Real Life’ to increase awareness of Eversense’s unique benefits


·Entered into a $50 million non-dilutive loan facility with Hercules Capital, Inc. and drew down an initial $25 million, further strengthening the balance sheet


“The third quarter was marked by milestones across our development programs, commercial collaboration with Ascensia, and continued progress in strengthening our balance sheet,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “Completing the adult cohort of the ENHANCE 365-day pivotal trial, launching a new advertising campaign and finalizing a new loan facility all help position us to advance our plans to grow adoption of Eversense, the world’s only long term CGM.”


Third Quarter 2023 Results:


Total revenue for the third quarter of 2023 was $6.1 million compared to $4.6 million for the third quarter of 2022. U.S. revenue was $3.9 million in the third quarter of 2023 compared to $1.9 million in the prior year period, and revenue outside the U.S. was $2.2 million in the third quarter of 2023 compared to $2.7 million in the prior year period.


Third quarter 2023 gross profit of $1.2 million increased from $0.8 million in gross profit for the third quarter of 2022. The increase in gross margin was primarily driven by an increase to revenue as volumes increased.


Third quarter 2023 sales and marketing and general and administrative expenses increased by $0.1 million year-over-year, to $7.4 million. The consistency was the result of efforts to manage other general and administrative costs across the organization.


Third quarter 2023 research and development expenses increased by $1.8 million year-over-year, to $12.8 million. The increase was primarily due to investments in our product pipeline for development and clinical trials of next generation technologies.


Net loss was $24.1 million, or $0.04 per share, in the third quarter of 2023 compared to a net loss of $60.4 million, or $0.13 per share, in the third quarter of 2022. Net income increased by $36.3 million due to the accounting for embedded derivatives, fair value adjustments and the exchange of a portion of the 2025 notes.


Cash, cash equivalents, short and long-term investments were $125.4 million and outstanding indebtedness was $45.8 million as of September 30, 2023.


2023 Financial Outlook


Senseonics expects full year 2023 global net revenue to be at the midpoint of the $20 million to $24 million range.





Conference Call and Webcast Information:


Company management will host a conference call at 4:30 pm (Eastern Time) today, November 9, 2023, to discuss these financial results and recent business developments. This conference call can be accessed live by telephone or through Senseonics' website.



Live Teleconference Information:

Dial in number: 888-317-6003

Entry Number: 1409312

International dial in: 412-317-6061

Live Webcast Information:

Visit http://www.senseonics.com and
select the "Investor Relations" section



A replay of the call can be accessed on Senseonics' website http://www.senseonics.com under "Investor Relations."


About Senseonics


Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.


Forward Looking Statements


Any statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue projections under "2023 Financial Outlook," statements about the commercial launch of Eversense® E3, statements regarding increasing patient access and patient and provider adoption, statements regarding advancing development programs and the pipeline, statements regarding strengthening the Eversense® brand, and other statements containing the words "believe," “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the commercial launch of Eversense® E3 CGM system and commercial expansion of the Eversense product, uncertainties inherent in the expansion of Ascensia Diabetes Care’s U.S. salesforce and its commercial initiatives, uncertainties inherent in partnering with the Nurse Practitioner Group and that partner’s assumption of certain clinical and administrative activities, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration of new technology, uncertainties relating to the current economic environment and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2022, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.


Investor Contact


Philip Taylor

Gilmartin Group







Senseonics Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)


   September 30,   December 31, 
   2023   2022 
Current assets:          
Cash and cash equivalents  $55,759   $35,793 
Short term investments, net   69,648    108,222 
Accounts receivable, net   701    127 
Accounts receivable, net - related parties   2,749    2,324 
Inventory, net   9,726    7,306 
Prepaid expenses and other current assets   7,557    7,428 
Total current assets   146,140    161,200 
Deposits and other assets   6,991    3,108 
Long term investments, net       12,253 
Property and equipment, net   934    1,112 
Total assets  $154,065   $177,673 
Liabilities and Stockholders’ Equity (Deficit)          
Current liabilities:          
Accounts payable  $2,669   $419 
Accrued expenses and other current liabilities   14,356    14,616 
Accrued expenses and other current liabilities, related parties   277    837 
Note payable, current portion, net       15,579 
Derivative liability, current portion       20 
Total current liabilities   17,302    31,471 
Long-term debt and notes payables, net   40,485    56,383 
Derivative liabilities   245    52,050 
Other liabilities   6,312    2,689 
Total liabilities   64,344    142,593 
Preferred stock and additional paid-in-capital, subject to possible redemption: $0.001 par value per share; 12,000 shares and 12,000 shares issued and outstanding as of September 30, 2023 and December 31, 2022   37,656    37,656 
Total temporary equity   37,656    37,656 
Commitments and contingencies          
Stockholders’ equity (deficit):          
Common stock, $0.001 par value per share; 900,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 528,176,273 shares and 479,637,138 shares issued and outstanding as of September 30, 2023 and December 31, 2022   528    480 
Additional paid-in capital   903,665    806,488 
Accumulated other comprehensive loss   (59)   (678)
Accumulated deficit   (852,069)   (808,866)
Total stockholders’ equity (deficit)   52,065    (2,576)
Total liabilities and stockholders’ equity  $154,065   $177,673 





Senseonics Holdings, Inc.

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except share and per share data)


   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Revenue, net  $426   $126   $1,176   $555 
Revenue, net - related parties   5,671    4,496    13,184    10,263 
Total revenue   6,097    4,622    14,360    10,818 
Cost of sales   4,925    3,866    12,358    8,711 
Gross profit   1,172    756    2,002    2,107 
Research and development expenses   12,769    10,985    38,003    28,088 
Selling, general and administrative expenses   7,425    7,340    22,598    23,785 
Operating loss   (19,022)   (17,569)   (58,599)   (49,766)
Other income (expense), net:                    
Interest income   1,460    544    3,879    878 
Gain (Loss) on fair value adjustment of option       (8,592)       41,333 
Exchange related gain (loss), net   (4,569)       14,207     
Interest expense   (2,425)   (4,801)   (9,388)   (13,806)
Gain (Loss) on change in fair value of derivatives   438    (28,948)   6,505    152,169 
Impairment cost, net       (984)       (138)
Other income (expense)   15    (41)   194    (112)
Total other (expense) income, net   (5,081)   (42,822)   15,397    180,324 
Net (Loss) Income   (24,103)   (60,391)   (43,202)   130,558 
Other comprehensive income (loss)                    
Unrealized gain (loss) on marketable securities   61    (57)   619    (973)
Total other comprehensive gain (loss)   61    (57)   619    (973)
Total comprehensive (loss) income  $(24,042)  $(60,448)  $(42,583)  $129,585 
Basic net (loss) income per common share  $(0.04)  $(0.13)  $(0.08)  $0.28 
Basic weighted-average shares outstanding   592,452,262    472,475,747    552,703,546    464,244,736 
Diluted net loss per common share  $(0.04)  $(0.13)  $(0.08)  $(0.10)
Diluted weighted-average shares outstanding   592,452,262    472,475,747    552,703,546    608,345,713 



Nov. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2023
Entity File Number 001-37717
Entity Registrant Name SENSEONICS HOLDINGS, INC.
Entity Central Index Key 0001616543
Entity Tax Identification Number 47-1210911
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 20451 Seneca Meadows Parkway
Entity Address, City or Town Germantown
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20876-7005
City Area Code 301
Local Phone Number 515-7260
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol SENS
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false

Senseonics (AMEX:SENS)
Graphique Historique de l'Action
De Jan 2024 à Fév 2024 Plus de graphiques de la Bourse Senseonics
Senseonics (AMEX:SENS)
Graphique Historique de l'Action
De Fév 2023 à Fév 2024 Plus de graphiques de la Bourse Senseonics